News & Articles

May 2020 – Heart Disease & Omega 6/3 Ratio



The ALP Newsletter
From Robert A. Barker, MD
This month we are focusing on reducing your risk of heart disease
A Note from Robert A. Barker, MD
Dear Reader,
According to the American Heart Association (AHA), 17.6 million deaths were caused by a cardiovascular disease in 2016. The AHA expects that number to increase to 23.6 million by 2030.
What are you doing to avoid becoming a part of that statistic?
The journal of Annals Internal Medicine produced an evidence map in 2019 displaying that “Omega-3 LC-PUFA use. . . could reduce risk of some cardiovascular outcomes in adults” (Khan, et. al 2019). In addition, research shows that non-natural forms of Omega 3’s are less absorbable by the body and do not help reduce your risk as efficiently as natural triglyceride forms (Vasquez, 2019).
Therefore, it is important to take a natural triglyceride form Omega 3s that are bioavailable to see the results proven by research (Vasquez, 2019). ALP High-3 has been engineered in its natural triglyceride form (rTG) for bioavailability and absorption. Continue your consumption of ALP High-3 to reduce your risk of a cardiovascular event.
Robert A. Barker, MD, Family Practice Physician
Did you know that your Omega 6/3 Ratio is one of the most important parts of your health? Are you taking the necessary steps to reduce your risk of chronic inflammatory disease and boost your everday well being? Re-order ALP High-3 Today.
Re-order ALP High-3

The Big Three

Three scholarly research articles to further your understanding of Omega 6/3 Ratios and their roles in reducing Chronic Inflammatory Disease

 My findings further supported the efficacy of n-3 PUFAs, especially EPA, in improving inattention and vigilance associated cognitive measures in ADHD with a low EPA level at baseline; and improving working memory and prosocial behavior in ADHD with high baseline inflammation status. Further research is needed to explore the effects of EPA on the clinical symptoms of ADHD targeting a larger sample size of youth with different nutritional and inflammatory status (Cheng, 2019).
Re-esterfied Triglyceride Form Fish Oil
Oral consumption of re-esterified omega-3 fatty acids is associated with statistically significant improvement in tear osmolarity, omega-3 index levels, TBUT, MMP-9, and OSDI symptom scores 
Joint Pain
Under inflammatory conditions, AA is released from the membrane . . . and this resulted in the formation of pro-inflammatory lipid mediators . . . which leads to further tissue damage, edema, and pain. Fish oil supplementation (3 g/day) reduced both incidence, from 93% to 69% (Gammone, Riccion, Parrinello, & D’Orazio, 2018). 

ALP Life Sciences is focused on advancing research in Applied Lipid Polymorphism (ALP – taking good fat to remove and remodel bad fat) to Combat the Global Epidemic of Chronic Inflammatory Disease

Please email us at info@alplifesciences.com or visit our Website
15 Jane Jacobs Rd., Suite 102
Black Mountain, North Carolina 28711
© 2019 ALP Life Sciences, LLC. All Rights Reserved
 alplifesciences.com | info@alplifesciences.com 


Want to Receive this Newsletter in your Inbox Each Month?

Fill out my online form